Structure via PubChem · Public domain (PubChem)
raloxifene
Sign in to saveAlso known as (2-(4-hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone
Raloxifene, sold under the brand name Evista among others, is a medication used to prevent and treat osteoporosis in postmenopausal women and those on glucocorticoids. For osteoporosis it is less preferred than bisphosphonates. It is also used to reduce the risk of breast cancer in those at high risk. It is taken by mouth.
Chemical data
- Formula
- C28H27NO4S
- Molecular weight
- 473.6 g/mol
- IUPAC name
- [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
- SMILES
- C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O
- InChIKey
- GZUITABIAKMVPG-UHFFFAOYSA-N
- XLogP
- 6.1
- Polar surface area
- 98.2 Ų
- H-bond donors
- 2
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 473.166
- Has use
- medication
Show 11 more facts
- chemical formula
- C₂₈H₂₇NO₄S
- defined daily dose
- 60.0
- canonical SMILES
- C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O
- World Health Organisation international non-proprietary name
- raloxifene
- subject has role
- selective estrogen-receptor modulators
- Commons category
- Raloxifene
- solubility
- 0.25
- partition coefficient water/octanol
- 5.2
- melting point
- 145
- medical condition treated
- bone disease
- legal status (medicine)
- boxed warning
via Wikidata · CC0
~12 min read
Encyclopedic overview
22 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Overdose
- Pharmacology
- Pharmacodynamics
- Mechanism of action
- Clinical effects
- Pharmacokinetics
- Absorption
- Distribution
- Metabolism
- Elimination
- Chemistry
- History
- Society and culture
- Names
- Availability
- Controversy
- Research
- References
- Further reading
Raloxifene, sold under the brand name Evista among others, is a medication used to prevent and treat osteoporosis in postmenopausal women and those on glucocorticoids. For osteoporosis it is less preferred than bisphosphonates. It is also used to reduce the risk of breast cancer in those at high risk. It is taken by mouth.
Common side effects include hot flashes, leg cramps, swelling, and joint pain. Severe side effects may include blood clots and stroke. Use during pregnancy may harm the baby. The medication may worsen menstrual symptoms. Raloxifene is a selective estrogen receptor modulator (SERM) and therefore a mixed agonist–antagonist of the estrogen receptor (ER). It has estrogenic effects in bone and antiestrogenic effects in the breasts and uterus.
Excerpted from Wikipedia’s “raloxifene” article, available under the CC BY-SA 4.0 licence.